Press Releases

BRUSSELS, Belgium and WASHINGTON, DC – February 16, 2017 – The Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the cell and gene therapy and broader regenerative medicine and advanced therapies sector, today announced it has published its position on Hospital Exemption (HE) in response to vastly different interpretations and implementations across the European Union of Article 3(7) of Directive 2001/83/EC within article 28 (2) of the Advanced Therapy Medicinal Products (ATMP) Regulation.

WASHINGTON, D.C., February 14, 2017 – The Alliance for Regenerative Medicine applauds the National Academies of Sciences, Engineering and Medicine for its very thorough and thoughtful report on the current scientific, technical, ethical, and policy issues relating to human genome editing.

WASHINGTON, D.C., February 2, 2017 – The Alliance for Regenerative Medicine (ARM) today announced its annual Cell & Gene Therapy Investor Day will take place April 27, 2017 in Boston, MA. The event is co-hosted by leading investment firm Piper Jaffray and held in partnership with Cowen & Co.

WASHINGTON, DC – January 30, 2017 – The Alliance for Regenerative Medicine (ARM) today announced it will host a free webinar titled “Understanding the 21st Century Cures Act for Cell & Gene Therapies.” During this one-hour live event, Michael Werner, Executive Director for ARM will be joined by Director Wilson W. Bryan, M.D., and Deputy Director Rachael F. Anatol, Ph.D., of the U.S.

WASHINGTON, DC – January 19, 2017 – The Alliance for Regenerative Medicine (ARM) today announced the formal launch of the international Standards Coordinating Body for regenerative medicines (SCB), a public-private partnership for coordinating, prioritizing and supporting standards that advances process, measurement and analytical techniques to support the global availability of products across the gene and gene-modified cell therapy, cell therapy, cell-based drug discovery, tissue engineering and biomaterials sectors.

WASHINGTON, D.C., December 15, 2016 – The Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the cell and gene therapies and broader regenerative medicine sector, announced its 2017 Cell & Gene Therapies State of the Industry briefing will take place January 9, 2017 in San Francisco, held in conjunction with Biotech Showcase™ 2017.

WASHINGTON, D.C., December 1, 2016 – The Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the gene and cellular therapies and broader regenerative medicine sector, commends the U.S. House of Representatives’ bipartisan passage of the 21st Century Cures Act.

WASHINGTON, D.C., November 17, 2016 – The Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the gene and cellular therapies and broader regenerative medicine sector, announced it will hold its Inherited Blood Disorders Clinical and Patient Education Roundtable December 13 in Washington, D.C., the third event in its patient roundtable series.

WASHINGTON, D.C., November 15, 2016 – The Alliance for Regenerative Medicine (ARM) today announced the launch of its three-part white paper series focused on the value and adoption of future gene and cell therapies.  The first paper, “Curative Regenerative Medicines: Preparing Health Care Systems for the Coming Wave” is available online today in In Vivo, a publication focusing on the global medical and healthcare ind

WASHINGTON, D.C., November 10, 2016 – The Alliance for Regenerative Medicine (ARM) today announced the release of its quarterly data report, offering an in-depth look at cell therapy, gene therapy, tissue engineering and broader global regenerative medicine sector trends and metrics in the third quarter of 2016.

Pages